Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 17:10:2333794X231156055.
doi: 10.1177/2333794X231156055. eCollection 2023.

Effects of Two Different Doses of Ursodeoxycholic Acid on Indirect Hyperbilirubinemia in Neonates with Glucose-6-phosphate Dehydrogenase Deficiency Treated with Phototherapy: A Randomized Controlled Trial

Roya Farhadi  1 , Elham Keyhanian  1 , Mohammad Naderisorki  2 , Aliasghar Nadi Ghara  3
Affiliations

Effects of Two Different Doses of Ursodeoxycholic Acid on Indirect Hyperbilirubinemia in Neonates with Glucose-6-phosphate Dehydrogenase Deficiency Treated with Phototherapy: A Randomized Controlled Trial

Roya Farhadi et al. Glob Pediatr Health. .

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the causes of severe hyperbilirubinemia, prolonged jaundice, and bilirubin-induced encephalopathy in neonates. In a randomized controlled trial, we evaluated the effect of oral ursodeoxycholic acid (UDCA) on indirect hyperbilirubinemia in G6PD-deficient neonates requiring phototherapy. Intervention group I (N = 45; received phototherapy and 10 mg/kg/day UDCA), Intervention group II (N = 40; received phototherapy and 20 mg/kg/day UDCA), and a control group (N = 49; received phototherapy and placebo). Levels of total serum bilirubin (TSB) in all 3 groups decreased significantly over time (P = .001) but the level of TSB at different hours after admission and the duration of phototherapy did not differ significantly between the 3 groups. After discharge, the 2 intervention groups had a significantly lower rate of readmission than the control group (P = .001). No significant difference was observed between the 10 and 20 mg/kg/day groups. Further evaluation is recommended, especially in terms of the pharmacokinetics of UDCA in neonates. Trial registration number: IRCT20091201002801N4, prospectively registered on 2019-06-1.

Keywords: glucose-6-phosphate dehydrogenase deficiency; hyperbilirubinemia; jaundice; newborn; ursodeoxycholic acid.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Diagram showing the flow of participants through the trial.
Figure 2.
Figure 2.
Time trend of total serum bilirubin changes among 3 groups.
See this image and copyright information in PMC

References

    1. Thielemans L, Trip-Hoving M, Landier J, et al. Indirect neonatal hyperbilirubinemia in hospitalized neonates on the Thai-Myanmar border: a review of neonatal medical records from 2009 to 2014. BMC Pediatr. 2018;18(1):190. - PMC - PubMed
    1. Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage–mechanisms and management approaches. New Engl J Med. 2013;369(21):2021-2030. - PubMed
    1. Isa HM, Mohamed MS, Mohamed AM, Abdulla A, Abdulla F. Neonatal indirect hyperbilirubinemia and glucose-6-phosphate dehydrogenase deficiency. Korean J Pediatr. 2017;60(4):106-111. - PMC - PubMed
    1. Khodashenas E, Kalani-Moghaddam F, Araghi Z, Khodaparast M, Yazdani Z. Glucose-6-phosphate dehydrogenase deficiency and neonatal hyperbilirubinemia. Iran J Neonatol. 2015;6(3):28-31.
    1. Cunningham AD, Hwang S, Mochly-Rosen D. Glucose-6-phosphate dehydrogenase deficiency and the need for a novel treatment to prevent Kernicterus. Clin Perinatol. 2016;43(2):341-354. - PMC - PubMed

LinkOut - more resources